Clinical trials
Active, not recruiting Anemia, Refractory, with Excess of Blasts trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
15 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2006 | 1 |
| 2012 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Active, not recruiting | 15 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 4 |
| Bellicum Pharmaceuticals | 1 |
| Celgene | 1 |
| City of Hope Medical Center | 1 |
| Fondazione Italiana Sindromi Mielodisplastiche-ETS | 1 |
| Fred Hutchinson Cancer Center | 1 |
| Liping Dou | 1 |
| Masonic Cancer Center, University of Minnesota | 1 |
| McMaster University | 1 |
| Nationwide Children's Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Anemia, Refractory, with Excess of Blasts | 15 |
| Myelodysplastic Syndromes | 9 |
| Leukemia, Myeloid, Acute | 6 |
| Hematologic Neoplasms | 4 |
| Leukemia | 4 |
| Leukemia, Myelomonocytic, Chronic | 4 |
| Lymphoma | 4 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 |
| Hodgkin Disease | 3 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 |
Trials
Showing 76 to 15 of 15. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.